AU2018231144B2 - Methods of treating and/or preventing actinic keratosis - Google Patents

Methods of treating and/or preventing actinic keratosis Download PDF

Info

Publication number
AU2018231144B2
AU2018231144B2 AU2018231144A AU2018231144A AU2018231144B2 AU 2018231144 B2 AU2018231144 B2 AU 2018231144B2 AU 2018231144 A AU2018231144 A AU 2018231144A AU 2018231144 A AU2018231144 A AU 2018231144A AU 2018231144 B2 AU2018231144 B2 AU 2018231144B2
Authority
AU
Australia
Prior art keywords
subject
affected area
days
day
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018231144A
Other languages
English (en)
Other versions
AU2018231144A1 (en
Inventor
David Lawrence CUTLER
Jane FANG
E. Douglas Kramer
Min-fun Rudolf Kwan
Johnson Yiu-Nam Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atnx Spv LLC
Original Assignee
Atnx Spv LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018231144(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv LLC filed Critical Atnx Spv LLC
Publication of AU2018231144A1 publication Critical patent/AU2018231144A1/en
Assigned to ATNX SPV, LLC reassignment ATNX SPV, LLC Request for Assignment Assignors: ATHENEX, INC.
Application granted granted Critical
Publication of AU2018231144B2 publication Critical patent/AU2018231144B2/en
Priority to AU2024201828A priority Critical patent/AU2024201828A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018231144A 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis Active AU2018231144B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201828A AU2024201828A1 (en) 2017-03-10 2024-03-20 Methods of treating and/or preventing actinic keratosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469889P 2017-03-10 2017-03-10
US62/469,889 2017-03-10
PCT/US2018/021929 WO2018165647A1 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201828A Division AU2024201828A1 (en) 2017-03-10 2024-03-20 Methods of treating and/or preventing actinic keratosis

Publications (2)

Publication Number Publication Date
AU2018231144A1 AU2018231144A1 (en) 2019-10-03
AU2018231144B2 true AU2018231144B2 (en) 2023-12-21

Family

ID=63446658

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018231144A Active AU2018231144B2 (en) 2017-03-10 2018-03-12 Methods of treating and/or preventing actinic keratosis
AU2024201828A Pending AU2024201828A1 (en) 2017-03-10 2024-03-20 Methods of treating and/or preventing actinic keratosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201828A Pending AU2024201828A1 (en) 2017-03-10 2024-03-20 Methods of treating and/or preventing actinic keratosis

Country Status (13)

Country Link
US (3) US10617693B2 (enExample)
EP (2) EP3592355B1 (enExample)
JP (3) JP7502863B2 (enExample)
KR (2) KR20190141661A (enExample)
CN (1) CN110891575A (enExample)
AU (2) AU2018231144B2 (enExample)
BR (1) BR112019018687A2 (enExample)
CA (1) CA3055938A1 (enExample)
IL (1) IL269182B2 (enExample)
MX (2) MX387658B (enExample)
TW (1) TWI841523B (enExample)
WO (1) WO2018165647A1 (enExample)
ZA (1) ZA202100106B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica
FI3679016T3 (fi) 2017-09-07 2025-12-12 Atnx Spv Llc 2-(5-(4-(2-morfolinoetoksi)fenyyli)pyridin-2-yyli)-n-bentsyyliasetamidin kiinteitä muotoja
CA3092939C (en) * 2018-03-07 2024-10-08 Atnx Spv, Llc USE OF THE COMBINATION OF KX01 AND VITAMIN D TO TREAT HYPERPROLIFERATIVE SKIN DISORDERS
WO2019188918A1 (ja) * 2018-03-28 2019-10-03 テルモ株式会社 医療デバイスおよび処置用法
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
EP4263833A1 (en) * 2021-01-21 2023-10-25 Sirnaomics, Inc. Compositions and methods for treatment of skin cancers
CN120152984A (zh) * 2023-10-13 2025-06-13 恩康药业科技（广州）有限公司 治疗和/或预防日光性角化病的化合物及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
DK1836169T5 (da) 2004-12-28 2023-10-09 Atnx Spv Llc Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
EP2041071B1 (en) 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
WO2008030892A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
WO2008144045A1 (en) 2007-05-17 2008-11-27 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2143421A1 (en) 2008-07-07 2010-01-13 Almirall Hermal GmbH Topical composition for the treatment of actinic keratosis
RS58566B1 (sr) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corp Formulacije imikuimoda niže dozne jačine i kratkih režima doziranja za lečenje aktinične keratoze
US8741857B1 (en) * 2012-01-30 2014-06-03 Lawrence Moy Treatments for actinic keratoses
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
BR112019018687A2 (pt) * 2017-03-10 2020-04-07 Athenex, Inc. métodos de tratamento e/ou prevenção da ceratose actínica

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"NCT02337205", CLINICALTRIALS.GOV, JPN6021045855, 2016, pages 1 - 4, ISSN: 0004643522 *
"NCT02838628", CLINICALTRIALS.GOV, JPN6021045856, 2016, pages 1 - 5, ISSN: 0004643523 *
KINEX PHARMACEUTICALS: "Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration. *

Also Published As

Publication number Publication date
KR20240090837A (ko) 2024-06-21
TWI841523B (zh) 2024-05-11
IL269182A (en) 2019-11-28
US10617693B2 (en) 2020-04-14
MX2019010707A (es) 2020-01-15
RU2019131757A3 (enExample) 2021-05-31
US11497750B2 (en) 2022-11-15
AU2024201828A1 (en) 2024-05-02
MX387658B (es) 2025-03-18
IL269182B1 (en) 2023-07-01
TW201842913A (zh) 2018-12-16
IL269182B2 (en) 2023-11-01
EP4659740A2 (en) 2025-12-10
KR20190141661A (ko) 2019-12-24
CN110891575A (zh) 2020-03-17
EP3592355B1 (en) 2025-12-10
WO2018165647A1 (en) 2018-09-13
JP2023015269A (ja) 2023-01-31
BR112019018687A2 (pt) 2020-04-07
ZA202100106B (en) 2022-08-31
AU2018231144A1 (en) 2019-10-03
EP3592355A1 (en) 2020-01-15
US20230172942A1 (en) 2023-06-08
US20180256589A1 (en) 2018-09-13
CA3055938A1 (en) 2018-09-13
RU2019131757A (ru) 2021-04-12
JP2025029010A (ja) 2025-03-05
MX2021013354A (es) 2021-11-18
US20200197405A1 (en) 2020-06-25
JP7502863B2 (ja) 2024-06-19
EP3592355A4 (en) 2021-01-06
JP2020510042A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
AU2018231144B2 (en) Methods of treating and/or preventing actinic keratosis
US20200352886A1 (en) Treatment of pain with topical diclofenac
US9974773B2 (en) Stabilized oxymetazoline formulations and their uses
KR20110021888A (ko) 여드름 관련 질환을 치료하기 위한 치료 요법
RU2805929C2 (ru) Способы лечения и/или предотвращения актинического кератоза
BR122025000862A2 (pt) Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
CA3003610A1 (en) Methods of treatment of acne vulgaris using topical dapsone compositions
Singh et al. Acne & Scars
Kircik Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne Guy Webster, Jefferson Medical College, Hoclessin, DE, United States; Michael Gold, MD, Tennessee Clinical, Nashville, TN, United States; Phoebe Rich, MD
WORCESTER Lactamide-MEA Gel Looks Good for Cradle Cap
NZ727233B2 (en) Stabilized oxymetazoline formulations and their uses
HK1236391A1 (en) Stabilized oxymetazoline formulations and their uses
HK1236391B (en) Stabilized oxymetazoline formulations and their uses

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ATNX SPV, LLC

Free format text: FORMER APPLICANT(S): ATHENEX, INC.

FGA Letters patent sealed or granted (standard patent)